Manufacturing, Cell Therapies

Cellectis Opens GMP Manufacturing Facility

October 22, 2021

A new GMP facility in Raleigh, NC, and a starting materials facility in Paris, France, give Cellectis end-to-end, in-house manufacturing capacity for its UCART product candidates.

Avid Bioservices Expands into Viral Vector Development and Manufacturing Services

October 14, 2021

Avid Bioservices is building a viral vector development and manufacturing facility near its existing biologics manufacturing facility in California.

NIIMBL Invests $3 Million in Six Biopharmaceutical Manufacturing Products

October 07, 2021

The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.

Repligen and Navigo GmbH Launch Industry-First Protein A Ligand for Purification of pH-Sensitive Antibodies

September 14, 2021

Repligen and Navigo’s novel ligand could be the first to address antibody aggregation in low pH elution buffers.

AGC Bio Boosts Manufacturing Capacity for pDNA and mRNA at Heidelberg Facility

September 14, 2021

AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.

Corning’s New Cell and Gene Therapy Platform Demonstrates Large-Scale Bioproduction

August 19, 2021

Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.

Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck

August 19, 2021

The collaboration will focus on the interactions between WTX-124 indukine and KEYTRUDA (pembrolizumab).

Artiva Biotherapeutics Builds New US Cell Therapy R&D and Manufacturing Facility

August 18, 2021

Artiva Biotherapeutics’s new R&D and GMP manufacturing center in San Diego, Calif., for NK cell therapies is expected to open in 2022.

Lykan Bioscience and Vineti Partner to Advance Cell Therapies from Clinic to Commercialization

August 13, 2021

Lykan Bioscience and Vineti will combine their capabilities to streamline process development and manufacturing to move cell therapies through clinical phases to commercialization.

Lonza and Sheba Medical Center Demonstrate Successful Cell Therapy Results with Cocoon Automated Platform

August 12, 2021

Lonza and Sheba Medical Center have successfully dosed four patients with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon automated manufacturing platform.